North Shore Hematology Oncology Associates PC
North Shore Hematology Oncology Associates PC was paid $61.66M by Medicaid between Jan 2018 and Dec 2024, across 214 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoNORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC
PORT JEFFERSON STATION, NY 11776
PORT JEFFERSON STATION, NY 11776
33aNPI1396794574assigned 05/08/2006
33bProvider typeSpecialist
28Total paid$61.66M
24GClaims1,890,558
24DCodes billed214
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in New York
Rank by total paid#2 of 1,221
Median peer was paid$45K
This provider vs. median1,363×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,490 | $553K | |
| 2019 | 67,971 | $1.39M | |
| 2020 | 138,284 | $3.12M | |
| 2021 | 232,283 | $6.96M | |
| 2022 | 371,577 | $11.88M | |
| 2023 | 547,345 | $19.82M | |
| 2024incomplete | 508,608 | $17.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 154,258 | 144,049 | $15.44M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.9% | 57,695 | 54,591 | $4.27M |
| 88185 | 4.6% | 6,532 | 6,481 | $2.82M | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 4.2% | 2,728 | 2,720 | $2.56M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.8% | 8,156 | 8,013 | $2.34M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.5% | 34,478 | 23,740 | $2.16M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.9% | 13,930 | 12,012 | $1.82M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.5% | 11,391 | 11,196 | $1.52M |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 2.4% | 2,002 | 1,458 | $1.49M |
| 80053 | Comprehensive metabolic panel | 2.2% | 155,857 | 142,709 | $1.33M |
| J1756 | Injection, iron sucrose, 1 mg | 2.0% | 24,773 | 16,334 | $1.25M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 256,335 | 211,958 | $1.22M |
202 more codes
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 2.0% | 4,076 | $1.21M |
| 99204 | Doctor's office visit, new patient (more involved) | 1.7% | 7,283 | $1.07M |
| 82728 | 1.7% | 91,638 | $1.06M | |
| 88189 | 1.5% | 15,652 | $923K | |
| 88120 | 1.4% | 2,529 | $877K | |
| 88377 | 1.3% | 1,756 | $780K | |
| 87481 | 1.1% | 10,083 | $691K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 2,695 | $667K |
| 51729 | 1.0% | 1,846 | $632K | |
| 82607 | 1.0% | 52,631 | $625K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 2,115 | $597K |
| 77014 | <1% | 5,993 | $567K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 6,281 | $546K |
| 83550 | <1% | 82,291 | $481K | |
| 99205 | Prolong outpt/office vis | <1% | 2,480 | $467K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 17,143 | $441K |
| 83540 | <1% | 88,421 | $430K | |
| 83615 | <1% | 92,041 | $427K | |
| 83735 | <1% | 87,803 | $421K | |
| 82746 | <1% | 34,465 | $387K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 3,393 | $373K |
| 84100 | <1% | 89,415 | $351K | |
| 72197 | <1% | 975 | $323K | |
| 88184 | <1% | 6,531 | $323K | |
| 84550 | <1% | 82,743 | $318K | |
| 87653 | <1% | 13,162 | $304K | |
| 76872 | <1% | 2,719 | $303K | |
| 88112 | <1% | 6,841 | $299K | |
| 87640 | <1% | 13,002 | $296K | |
| 87500 | <1% | 11,706 | $270K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 10,340 | $249K |
| 76775 | <1% | 4,456 | $244K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,425 | $243K |
| 74178 | <1% | 799 | $233K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,862 | $222K |
| 51784 | <1% | 3,840 | $213K | |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | <1% | 52 | $212K |
| 76770 | <1% | 2,164 | $189K | |
| 51728 | <1% | 1,015 | $188K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,429 | $182K |
| 76830 | Ultrasound, transvaginal | <1% | 1,648 | $174K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 524 | $168K |
| 74183 | <1% | 458 | $162K | |
| 84403 | <1% | 7,519 | $158K | |
| 84153 | <1% | 11,201 | $158K | |
| 76857 | <1% | 4,297 | $158K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,394 | $151K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,403 | $146K |
| 86334 | <1% | 7,656 | $140K | |
| 82378 | <1% | 8,304 | $130K | |
| 82784 | <1% | 7,337 | $129K | |
| 80050 | General health panel | <1% | 4,293 | $125K |
| 93976 | <1% | 896 | $124K | |
| 51741 | <1% | 7,975 | $114K | |
| 71250 | <1% | 714 | $95K | |
| 87641 | <1% | 4,321 | $90K | |
| 77427 | <1% | 572 | $82K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,300 | $81K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,399 | $80K |
| 51798 | <1% | 7,598 | $80K | |
| 82670 | <1% | 3,340 | $78K | |
| 83521 | <1% | 3,514 | $78K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 523 | $77K |
| 80061 | Lipid panel | <1% | 9,244 | $74K |
| 84165 | <1% | 8,353 | $69K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 602 | $68K |
| 87529 | <1% | 1,103 | $67K | |
| 52000 | <1% | 323 | $65K | |
| 86300 | <1% | 3,767 | $64K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,786 | $64K |
| 81002 | <1% | 28,274 | $62K | |
| 85044 | <1% | 22,032 | $56K | |
| 96127 | <1% | 15,682 | $56K | |
| 76641 | <1% | 397 | $52K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 474 | $52K |
| 88360 | <1% | 642 | $50K | |
| 84146 | <1% | 3,120 | $48K | |
| 88344 | <1% | 291 | $48K | |
| 83001 | <1% | 3,116 | $48K | |
| 83002 | <1% | 3,098 | $47K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,411 | $46K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 399 | $46K |
| 77049 | <1% | 137 | $44K | |
| 88342 | <1% | 556 | $39K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 832 | $39K |
| 77336 | <1% | 587 | $37K | |
| 83010 | <1% | 3,021 | $32K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 642 | $31K |
| 76870 | <1% | 400 | $31K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 282 | $30K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 194 | $29K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,088 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,038 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,076 | $27K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,113 | $26K |
| 64566 | <1% | 288 | $26K | |
| 88341 | <1% | 318 | $25K | |
| 51792 | <1% | 93 | $25K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 3,022 | $25K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,999 | $24K |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 137 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 502 | $23K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,671 | $21K |
| 96367 | <1% | 492 | $21K | |
| 84436 | <1% | 2,596 | $14K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 8,129 | $13K |
| 81025 | <1% | 2,676 | $13K | |
| 70491 | <1% | 66 | $11K | |
| 76536 | <1% | 110 | $11K | |
| 38222 | <1% | 76 | $10K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 54 | $10K |
| 77012 | <1% | 74 | $8K | |
| 82947 | <1% | 1,835 | $8K | |
| 51797 | <1% | 69 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 343 | $7K |
| 99385 | <1% | 57 | $7K | |
| 85651 | <1% | 2,601 | $7K | |
| 80047 | <1% | 764 | $7K | |
| 88368 | <1% | 61 | $6K | |
| 87511 | <1% | 277 | $6K | |
| 97803 | <1% | 287 | $6K | |
| 97802 | <1% | 151 | $6K | |
| 93000 | <1% | 455 | $6K | |
| 99442 | <1% | 74 | $6K | |
| 90674 | <1% | 184 | $5K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 135 | $5K |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 236 | $5K |
| 84479 | <1% | 1,284 | $5K | |
| 84439 | <1% | 627 | $4K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 105 | $4K |
| 82668 | <1% | 259 | $4K | |
| 80074 | <1% | 98 | $4K | |
| 84270 | <1% | 226 | $4K | |
| 99417 | Prolong home eval add 15m | <1% | 135 | $4K |
| 88108 | <1% | 79 | $4K | |
| 76642 | <1% | 39 | $3K | |
| 88369 | <1% | 12 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,700 | $3K |
| 99490 | Ccm add 20min | <1% | 379 | $3K |
| 71271 | <1% | 27 | $3K | |
| 90682 | <1% | 42 | $3K | |
| 77300 | <1% | 27 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 317 | $3K |
| 86301 | <1% | 205 | $3K | |
| 82232 | <1% | 249 | $3K | |
| 86304 | <1% | 185 | $2K | |
| 82248 | <1% | 570 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 61 | $2K |
| 77334 | <1% | 12 | $2K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 27 | $2K |
| 93970 | <1% | 13 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 14 | $2K |
| 76818 | <1% | 16 | $2K | |
| 81000 | <1% | 472 | $2K | |
| 0012A | <1% | 48 | $2K | |
| 85610 | <1% | 470 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 49 | $2K |
| 82565 | <1% | 334 | $1K | |
| 85014 | <1% | 757 | $1K | |
| 88374 | <1% | 26 | $1K | |
| 90661 | <1% | 39 | $1K | |
| 82785 | <1% | 117 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 19 | $1K |
| 86141 | <1% | 136 | $1K | |
| 99497 | <1% | 15 | $1K | |
| 84520 | <1% | 308 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 932 | $932.91 |
| 96417 | <1% | 13 | $890.86 | |
| 0011A | <1% | 28 | $853.74 | |
| 97162 | <1% | 12 | $840.73 | |
| 76377 | <1% | 16 | $839.35 | |
| 82627 | <1% | 42 | $801.39 | |
| 85730 | <1% | 143 | $724.88 | |
| 86800 | <1% | 63 | $683.98 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 960 | $628.14 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 91 | $627.55 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 97 | $622.46 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 19 | $605.67 |
| 86431 | <1% | 121 | $598.71 | |
| 84154 | <1% | 27 | $494.94 | |
| 82043 | <1% | 113 | $462.86 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 34 | $430.33 |
| 86147 | <1% | 14 | $412.37 | |
| 86146 | <1% | 14 | $412.37 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 866 | $322.34 |
| 90756 | <1% | 19 | $291.94 | |
| 82550 | <1% | 54 | $267.61 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $235.89 |
| 82247 | <1% | 185 | $235.48 | |
| 83690 | <1% | 47 | $229.53 | |
| 85060 | <1% | 13 | $228.52 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 78 | $168.39 |
| 80076 | <1% | 25 | $156.05 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 17 | $114.41 |
| 86038 | <1% | 13 | $97.17 | |
| 84478 | <1% | 14 | $70.48 | |
| 82465 | <1% | 14 | $59.51 | |
| 85536 | <1% | 12 | $44.67 | |
| 82310 | <1% | 13 | $28.13 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 18 | $9.83 |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 67 | $1.70 |
| 0502F | 0% | 530 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDANDRAIA, PATRICIA (CREDENTIALING COORDINATOR)
| Provider | Location | Paid |
|---|---|---|
| North Shore Hematology Oncology Associates PC | Poughkeepsie, NY | $731K |
| North Shore Hematology Oncology Associates PC | New Hyde Park, NY | $153K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.